Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 11, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-04
DOI
10.1038/s41408-021-00529-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis
- (2021) Jose Acevedo et al. Clinical Lymphoma Myeloma & Leukemia
- Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study
- (2020) Vaishali Sanchorawala et al. BLOOD
- Epidemiologic and Survival Trends in Amyloidosis, 1987–2019
- (2020) Sriram Ravichandran et al. NEW ENGLAND JOURNAL OF MEDICINE
- AL Amyloidosis in Myeloma: Red Flag Symptoms
- (2020) Lisa Mendelson et al. Clinical Lymphoma Myeloma & Leukemia
- Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis
- (2020) Amanda Schulman et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Systemic Amyloidosis due to Low-Grade Lymphoma
- (2020) Ashutosh D. Wechalekar et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library
- (2019) Robert A. Kyle et al. MAYO CLINIC PROCEEDINGS
- Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
- (2019) Surbhi Sidana et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
- (2019) Eli Muchtar et al. BRITISH JOURNAL OF HAEMATOLOGY
- A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom
- (2019) Faye A. Sharpley et al. BRITISH JOURNAL OF HAEMATOLOGY
- Non-lymphoplasmacytic lymphomas underlying light chain amyloidosis: distinct clinical features and outcome
- (2019) Marco Basset et al. BLOOD
- IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
- (2019) Surbhi Sidana et al. LEUKEMIA
- Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
- (2018) Brian Lilleness et al. BLOOD
- Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
- (2016) V. Sanchorawala et al. BLOOD
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
- (2016) Morie A. Gertz et al. JOURNAL OF CLINICAL ONCOLOGY
- Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
- (2015) Isabelle Lousada et al. ADVANCES IN THERAPY
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
- (2015) V. Sanchorawala et al. BLOOD
- A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
- (2015) G. Palladini et al. BLOOD
- Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis
- (2015) S. Sachchithanantham et al. HAEMATOLOGICA
- Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis
- (2015) K. M. Bever et al. HAEMATOLOGICA
- Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis
- (2015) S. Sachchithanantham et al. HAEMATOLOGICA
- Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis
- (2015) K. M. Bever et al. HAEMATOLOGICA
- A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
- (2014) G. Palladini et al. BLOOD
- Natural history and therapy of AL cardiac amyloidosis
- (2014) Martha Grogan et al. HEART FAILURE REVIEWS
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
- (2012) A. Dispenzieri et al. BLOOD
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score
- (2010) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started